invoX Pharma agrees to acquire biopharma firm F-star Therapeutics for $161m
Four programmes of F-star are currently in the clinic while various other undisclosed programmes are in the developmental stage.
Oncology
Latest in
Oncology
EC approves Novartis’ Tabrecta for non-small cell lung cancer
The EC approval is based on positive findings from the Phase II GEOMETRY mono-1 clinical trial of Tabrecta.
MD Anderson, Invectys and CTMC partner to develop CAR T cell therapy
Invectys’ researchers and the CTMC team will jointly develop an HLA-G targeted CAR T cell therapy for solid tumours.
FDA grants IND clearance for Jazz and Redx’s cancer drug application
The clinical development has triggered a milestone payment of $5m payable by Jazz to Redx.
Evgen Pharma and University of Michigan to study colorectal cancer asset
The parties will assess the in vivo effects of SFX-01 in models of colorectal cancer.
China NMPA grants approval for BeiGene’s nasopharyngeal cancer therapy
The approval is based on clinical data from the Phase III RATIONALE 309 clinical trial of tislelizumab plus chemotherapy.
Everest’s Trodelvy receives approval for breast cancer in China
In a Phase IIb trial in 80 subjects, Trodelvy offered an overall response rate of 38.8%.
China’s NMPA accepts Innovent and IASO Bio’s multiple myeloma therapy NDA
The acceptance of NDA is based on data obtained from an open-label, multi-centre, single-arm Phase I/II study.